Literature DB >> 21194964

FGF21 reloaded: challenges of a rapidly growing field.

Alexei Kharitonenkov1, Philip Larsen.   

Abstract

Fibroblast growth factor 21 (FGF21) is a pleiotropic hormone-like protein and a major metabolic regulator. However, several key aspects of FGF21 biology remain poorly understood. Indeed, the list of controversies in the FGF21 field spans a variety of topics, from basic matters such as the anatomic distribution of FGF21 expression and the molecular composition of the FGF21 receptor, to the ultimate question of therapeutic relevance of FGF21-dependent pathways in humans. In this paper, we focus on current challenges in the field in an attempt to provide a balanced overview of FGF21 biology and guide future research into this exciting metabolic target.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21194964     DOI: 10.1016/j.tem.2010.11.003

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  60 in total

1.  Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21.

Authors:  Holly A Cyphert; Xuemei Ge; Alison B Kohan; Lisa M Salati; Yanqiao Zhang; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

2.  Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.

Authors:  S L Samson; P Sathyanarayana; M Jogi; E V Gonzalez; A Gutierrez; R Krishnamurthy; R Muthupillai; L Chan; M Bajaj
Journal:  Diabetologia       Date:  2011-09-29       Impact factor: 10.122

3.  The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue.

Authors:  Andrew C Adams; Chaofeng Yang; Tamer Coskun; Christine C Cheng; Ruth E Gimeno; Yongde Luo; Alexei Kharitonenkov
Journal:  Mol Metab       Date:  2012-08-28       Impact factor: 7.422

4.  Lipodystrophy HIV-related and FGF21: A new marker to follow the progression of lipodystrophy?

Authors:  Stefano Benedini; Livio Luzi
Journal:  J Transl Int Med       Date:  2016-12-30

Review 5.  Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk.

Authors:  Jennifer H Stern; Joseph M Rutkowski; Philipp E Scherer
Journal:  Cell Metab       Date:  2016-05-10       Impact factor: 27.287

6.  Interplay between FGF21 and insulin action in the liver regulates metabolism.

Authors:  Brice Emanuelli; Sara G Vienberg; Graham Smyth; Christine Cheng; Kristin I Stanford; Manimozhiyan Arumugam; Mervyn D Michael; Andrew C Adams; Alexei Kharitonenkov; C Ronald Kahn
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

7.  Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.

Authors:  Takashi Shida; Kentaro Akiyama; Sechang Oh; Akemi Sawai; Tomonori Isobe; Yoshikazu Okamoto; Kazunori Ishige; Yuji Mizokami; Kenji Yamagata; Kojiro Onizawa; Hironori Tanaka; Hiroko Iijima; Junichi Shoda
Journal:  J Gastroenterol       Date:  2017-08-08       Impact factor: 7.527

Review 8.  Muscle-Adipose Tissue Cross Talk.

Authors:  Kristin I Stanford; Laurie J Goodyear
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

9.  Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients.

Authors:  J M Gallego-Escuredo; J Gómez-Ambrosi; V Catalan; P Domingo; M Giralt; G Frühbeck; F Villarroya
Journal:  Int J Obes (Lond)       Date:  2014-05-12       Impact factor: 5.095

10.  Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones.

Authors:  Andrew C Adams; Tamer Coskun; Christine C Cheng; Libbey S O Farrell; Susan L Dubois; Alexei Kharitonenkov
Journal:  Mol Metab       Date:  2013-05-29       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.